Nuritas Secures Series C Investment from McWin to Amplify AI-Powered Peptide Platform
Deal News | Dec 20, 2024 | McWin Capital Partners
McWin Capital Partners, a private equity and venture capital firm focused on the food ecosystem, has invested in Nuritas, a biotechnology company based in Dublin. The investment is part of Nuritas' oversubscribed €40 million Series C funding round, conducted alongside M&G's Catalyst Capital Fund and other investors such as Grosvenor and ECBF. Nuritas leverages its proprietary AI-driven platform to discover bioactive peptides that provide health benefits. With a strong roster of investors and partners that includes companies like Givaudan and Nestlé, Nuritas is positioned to expand its product line and commercial presence. This financial injection will support the company's plans to release new products yearly, with McWin's co-founder Henry McGovern joining the board to aid in their strategic growth.
Sectors
- Biotechnology
- Private Equity
- Food Technology
Geography
- United Kingdom – McWin Capital Partners is based in London and operates under UK regulation.
- Ireland – Nuritas, the biotechnology company receiving the investment, is headquartered in Dublin, Ireland.
Industry
- Biotechnology – Nuritas operates within the Biotechnology sector, focusing on the discovery and development of bioactive peptides using AI technologies.
- Private Equity – McWin Capital Partners, a major participant in this deal, is a private equity firm investing in innovative companies within the food tech ecosystem.
- Food Technology – McWin Capital is focused on transformative changes in the food industry, supporting businesses that innovate in food technology.
Financials
- 40 million – Amount raised in Nuritas' Series C funding round.
- 5 billion – Size of M&G's Catalyst Capital Fund participating in the Nuritas investment.
- 1 billion – Total capital raised by McWin across three funds.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Nuritas | Target Company | Company | A Dublin-based biotechnology firm pioneering in AI-powered peptide discovery. |
| McWin Capital Partners | Investor | Company | A specialist private equity and venture capital firm devoted to the food ecosystem. |
| M&G's Catalyst Capital Fund | Co-Investor | Company | A growth-stage investment vehicle focusing on health, climate, and enabling technologies. |
| Grosvenor | Co-Investor | Company | A company participating in Nuritas' Series C funding round. |
| ECBF | Co-Investor | Company | Another investor joining the Series C funding for Nuritas. |
| Henry McGovern | Board Member | Person | Co-founder of McWin Capital Partners; set to join the Nuritas Board of Directors. |
| Martin Davalos | Partner & Head of Food Tech | Person | A partner at McWin, contributing to the investment in Nuritas. |
| Cleveland Avenue | Prior Investor | Company | Previously invested in Nuritas before the Series C round. |
| Givaudan | Partner/Customer | Company | A partner and customer of Nuritas, involved in food and flavors. |
| Nestlé | Partner/Customer | Company | One of Nuritas' partners and customers, a global food and beverage leader. |
| Mars | Partner/Customer | Company | A global company engaged with Nuritas as a partner/customer. |
| Sumitomo Corporation | Partner/Customer | Company | A major corporation partnered with Nuritas. |